Ras v12-mediated down-regulation of CCAAT/enhancer binding protein β in immortalized fibroblasts requires loss of p19 Arf and facilitates bypass of oncogene-Lnduced senescence

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2588-2598

  Sebastian, Thomas ^a   Johnson, Peter F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P16; PROTEIN P19; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; CDKN2A PROTEIN, MOUSE; FAS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CELL AGING; CELL CYCLE ARREST; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; FIBROBLAST; GENE DELETION; GENE LOCUS; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; BIOSYNTHESIS; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD95; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; FIBROBLASTS; GENES, RAS; HUMANS; MICE; NIH 3T3 CELLS; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 65549139415     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2312     Document Type: Article

References (49)

1. Rodriguez -Viclana P, Tetsu 0, Oda K, et al. Cancer Targets in the Kas Pathway. Cold Spring Harb Symp Quant Biol 2005;70:461-7.
2. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and pl6IKK4a. Cell 1997;88:593-602.
3. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432:307-15.
4. Pruitt K, Der CJ. Kas and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 2001;171:1-10.
5. Fenton RG, Hixon JA, Wright PW, Brooks AD, Sayers TJ. Inhibition of Fas (CD95) expression and Fas- mediated apoptosis by oncogenic Ras. Cancer Res 1998;58:3391-400.
6. Pell j, Schroter M, Rudaz C, et al. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulat- ing the expression of Fas. EMBO J 1999;18:1824-31.
7. Guan RJ, Fu Y, Holt PR, Pardee AB. Association of K- ras mutations with pl6 methylation in human colon cancer. Gastroenterology 1999;116:1063-71.
8. Contente S, Kenyon K, Sriraman P, Subramanyan S, Friedman RM. Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene. Mol Cell Biochem 1999;194:79-91.
9. Pruitt K, Ulku AS, Frantz K, et al. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem 2005;280:23363-70.
10. Shields JM, Mehta H, Pruitt K, Der CJ. Opposing roles of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in Ras- mediated downregulatlon of tropomyosin. Mol Cell Biol 2002;22:2304-17.
11. Vasudevan KM, Burikhanov R, Goswami A, Rangne- kar VM. Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res 2007;67:10343-50.
12. Jiang K, Sun J, Cheng J, et al. Akt mediates Ras downregulatlon of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol 2004;24: 5565-76.
13. Rong R, Montalbano J, Jin W, et al. Oncogenic Ras- mediated downregulatlon of Gaddl53/CHOP is required for Ras-induced cellular transformation. Oncogene 2005; 24:4867-72.
14. Shin SY, Bahk YYS Ko J, et al. Suppression of Egr-1 transcription through targeting of the serum response factor by oncogenic H-Ras. EMBO J 2006;25:1093-103.
15. Yang JY, Zong CS, Xia W, et al. ERK promotes tumorigenesis by inhibiting FOX03a via MDM2-mediated degradation. Mat Cell Biol 2008;10:138-48.
16. Mo X, Kowenz-Leutz E, Xu H, Leutz A. Ras induces mediator complex exchange on C/EBPβ, Mol Cell 2004; 13:241-50.
17. Shuman JD, Sebastian T, Kaldis P, et al. Cell cycle- dependent phosphorylation of C/EBPβ mediates oncogenic cooperativity between C/EBPβ and H-RasV12. Mol Cell Biol 2004;24:7380-91.
18. Nakajima T, Kinoshita S, Sasagawa T, et al. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci USA 1993;90:2207-11.
19. Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC. CCAAT/enhancer binding protein-β is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Kas signaling. Proc Natl Acad Sci USA 2002; 99:207-12.
20. Wessells J, Yakar S, Johnson PF. Critical prosur- vival roles for C/EBPβ and Insulin-like growth factor I in macrophage tumor cells. Mol Cell Biol 2004;24: 3238-50.
21. Sebastian T, Johnson PF. Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPβ. Cell Cycle 2006;5:953-7.
22. Sebastian T, Malik R, Thomas S, Sage J, Johnson PF. C/EBPβ cooperates with RB/E2F to implement Ras(V12)-induced cellular senescence. EMBO J 2005;24: 3301-12.
23. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleu- kin-dependent inflammatory network Cell 2008;133: 1019-31.
24. Acosta JC, O'Loghlen A, Banito A, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008;133:1006-18.
25. Serrano M, Lee H( Chin L, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85:27-37.
26. Harvey M, Sands AT, Weiss KS, et al. In vitro growth characteristics of embryo fibroblasts isolated from p53- deficient mice. Oncogene 1993;8:2457-67.
27. Chen Z, Torrens JI( Anand A, Spiegelman BM, Friedman JM. Krox20 stimulates adipogenesis via C/EBP[β]-dependent and -independent mechanisms. Cell Metah 2005;1:93-106.
28. Verbeyre G, de Stan china E, Lin AW, et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 2002;22:3497-508.
29. Baer M, Johnson PF. Generation of truncated C/EBPβ isoforms by in vitro proteolysis, J Biol Chem 2000;275:26582-90.
30. Gazin C, Wajapeyee K, Gobeil S, Virhasius CM, Green MR. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007;449:1073-7.
31. Descombes P, Schibler U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 1991;67:569-79.
32. Ramji DP, Poka P. CCAAT/enhaneer-binding proteins: structure, function and regulation. Biochem J 2002;365:561-75.
33. Raught B, Gingras AC, James A, et al. Expression of a translationally regulated, dominant-negative CCAAT/ enhancer-binding protein β isoform and up-regulation of the eukaryotic translation Initiation factor 2α are correlated with neoplastic transformation of mammary epithelial cells. Cancer Res 1996;56:4382-6.
34. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. BRAF(E600) in benign and malignant human tumours. Oncogene 2008;27:877-95.
35. Quelle DE, Zindy F, Ashmun RA, Sherr Cj. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
36. Darville MI, Eizirik DL. Cytokine induction of Fas gene expression in insulin-producing cells requires the transcription factors NF-kB and C/EBP. Diabetes 2001; 50:1741-8.
37. Wada M, Matsumura M, Ohba Y, et al. Transcription stimulation of the Fas-encoding gene by nuclear factor for interIeukin-6 expression upon influenza virus infection. J Biol Chem 1995;270:18007-12.
38. Kessler R, Zacharova-Albinger A, Laursen NB, Kalousek M, Klemenz R. Attenuated expression of the serum responsive Tl gene in ras transformed fibroblasts due to the inhibition of c-fos gene activity. Oncogene 1999;18:1733-44.
39. Weber JD, Jeffers JR, Rehg JE, et al. p53-independent functions of the pl9(ARF) tumor suppressor. Genes Dev 2000;14:2358-65.
40. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006;6:663-73.
41. Ruo ML, Duneavage EJ, Mathew R, et al. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res 2003;63:1046-53.
42. Qi Y, Gregory MA, Li Z, et al. pl9ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 2004;431:712-7.
43. Datta A, Nag A, Pan W, et al. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J Biol Chem 2004;279:36698-707.
44. Amente S, Gargano B, Diolaiti D, et al. pl4ABF interacts with N-Myc and inhibits its transcriptional activity. FEBS Lett 2007;581:821-5.
45. 1 arrest function of ARF. Mol Cell Biol 2005;25:8024-36.
46. Johnson PF. Molecular stop signs: regulation of cell- cycle arrest by C/EBP transcription factors. J Cell Sci 2005;118:2545-55.
47. Parkin SE, Baer M, Copeland TD, Schwartz RC, Johnson PF. Regulation of CCAAT/enhancer-binding protein (C/EBP) activator proteins by heterodirnerization with C/EBPγ (Ig/EBP). J Biol Chem 2002;277:23563-72.
48. Cooper C, Henderson A, Artandi S, Avitahl N, Calame K. Ig/EBP (C/EBP -γ) is a transdominant negative inhibitor of C/EBP family transcriptional activators. Nucleic Acids Res 1995;23:4371-7. 49- Vallejo M, Ron D, Miller CP, Habener JF. C/ATF, a member of the activating transcription factor family of DNA-binding proteins, dimerizes with CAAT/enhancer- binding proteins and directs their binding to cAMP response elements. Proc Natl Acad Sci U S A 1993;90: 4679-83.
49. Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J. C/EBP at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 2006;10:203-14.